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losclerosis, and one with membranoproliferative glomer- Criteria for calcimimetic agent
ulonephritis). The other seven patients were clinically
diagnosed with chronic renal failure. Twelve urine and in the treatment of more
serum samples were collected from three patients with
ischemic acute renal failure. As VEGF concentration in severe secondary
the urine did not change after 24 hours’ incubation at
room temperature, those urine samples were stored at hyperparathyroidism
2308C until use and submitted to colorimetric enzyme
immunoassay to quantitate VEGF. Renal function was To the Editor: The prevention and treatment of sec-
ondary hyperparathyroidism still are challenging for theevaluated by 24-hour creatinine clearance (CCr).
There was an inverse relationship between urinary nephrologist. Therefore, the recent work of Goodman
et al is very interesting and promising [1]. The goal ofexcretion of VEGF and CCr (Fig. 1A). VEGF excretion
in urine did not correlate with its serum (Fig. 1B) or their study was to assess the safety and efficacy of a
calcimimetic agent in dialysis patients with modest toplasma level (data not shown). In patients with acute
renal failure, no correlation was observed between uri- severe secondary hyperparathyroidism. However, their
study appears to focus only on a single criterion fornary excretion of VEGF and CCr (Fig. 1C).
We examined patients with a wide range of renal func- modest or severe secondary hyperparathyroidism, the
level of intact parathyroid hormone (PTH). It is welltions to focus on the relationship between urinary VEGF
and renal function. In patients with chronic renal failure, known that secondary hyperparathyroidism is a state of
increased synthesis and secretion of PTH, but also a stateVEGF excretion in urine increased as renal function
of increased hypertrophy and particularly hyperplasia ofdecreased. Since excretion was independent of the serum
the parathyroid cells [2]. There are two forms of parathy-level of VEGF, urinary VEGF appears to be derived
roid gland hyperplasia, diffuse and nodular. Parathyroidfrom the kidney. Therefore, increased excretion of
glands with nodular hyperplasia are larger. In 90% ofVEGF suggests its increased secretion in residual neph-
parathyroid glands weighing 0.5 g nodular hyperplasiarons under diffuse and continuous hypoxia. In patients
was found. Such nodules are made of cells with signifi-with acute renal failure, urinary VEGF excretion was
cantly reduced numbers of vitamin D receptors, calcium-independent of renal function, probably because excre-
sensing receptors (CaSR), and a higher calcium set pointtion of VEGF from the kidney did not change much
for PTH secretion. From a clinical point of view, it issince the ischemic period was transient and the area was
important to note that patients with nodular parathyroidlimited. Although further studies are needed, urinary
gland hyperplasia are often resistant to calcitriol therapy.VEGF might be a unique indicator of renal hypoxia.
Today, high-resolution sonography is the best tech-
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Despite these remarks, we hope that a new calcimi-
metic agent, as well as new phosphate binders and newREFERENCES
vitamin D analogues, will be useful in the treatment of
1. Ostendorf T, Kunter U, Eitner F, et al: VEGF(165) mediates dialysis patients.
glomerular endothelial repair. J Clin Invest 104:913–923, 1999
2. Honkanen E, Teppo A-M, Gro¨nhagen-Riska C: Decreased urinary
Drasko Pavlovic and Hrvojka Tomic Brzacexcretion of vascular endothelial growth factor in idiopathic mem-
Zagreb, Croatiabranous glomerulonephritis. Kidney Int 57:2343–2349, 2000
3. Awad BL, Kreft B, Wolber E-M, et al: Hypoxia and interleukin-
Correspondence to Drasko Pavlovic, M.D., Ph.D., “Sveti Duh” Gen-1b stimulate vascular endothelial growth factor production in human
eral Hospital, 10000 Zagreb, Sveti Duh 64, Croatia.proximal tubular cells. Kidney Int 58:43–50, 2000
E-mail: drasko.pavlovic@bol-svduh.tel.hr4. Kanellis J, Mudge S, Fraser S, et al: Redistribution of cytoplasmic
VEGF to the basolateral aspect of renal tubular cells in ischemia-
reperfusion injury. Kidney Int 57:2445–2456, 2000 REFERENCES
1. Goodman WG, Frazao JM, Goodkin DA, et al: A calcimimetic
agent lowers plasma parathyroid hormone levels in patients with
secondary hyperparathyroidism. Kidney Int 58:436–445, 2000Ó 2001 by the International Society of Nephrology
Letters to the Editor 387
2. Parfitt AM: The hyperparathyroidism of chronic renal failure: A Correspondence to George Haycock, FRCP, Academic Department
of Paediatrics, 12th Floor, Guy’s Tower, Guy’s Hospital, London SE1disorder of growth. Kidney Int 52:3–9, 1997
9RT, England, United Kingdom.3. Pavlovic D, Tomic Brzac G, Cala S, Jankovic N: The value of
E-mail: ghayc37893@aol.comparathyroid sonography in secondary hyperparathyroidism. Nephrol
Dial Transplant 12:367, 1997
REFERENCES
1. Man˜alich R, Reyes L, Herrera M, et al: Relationship between
weight at birth and the number and size of renal glomeruli inRelationship between birth
humans: A histomorphometric study. Kidney Int 58:770–773, 2000
2. Hinchcliffe SA, Lynch MRJ, Sargent PH, et al: The effect ofweight, glomerular number, intrauterine growth retardation on the development of renal neph-
rons. Br J Obstet Gynaecol 99:296–301, 1992
3. Merlet-Be´nichou C, Gilbert T, Muffat-Joly M, et al: Intrauter-and glomerular size ine growth retardation leads to a permanent nephron deficit in the
rat. Pediatr Nephrol 8:175–180, 1994To the Editor: In a recent issue of Kidney International
Man˜alich et al confirm previous reports of a positive Reply from the authors
relationship between birth weight and glomerular num- We used the value of 2500 g to divide “low” from
ber, and describe an inverse relationship between birth “normal” weight at birth in our infants, regardless of
weight and glomerular size, a novel observation [1]. It whether the gestation was 36 or 41 weeks, following the
is regrettable, however, that they chose the arbitrary guidelines of the World Health Organization [1, 2]. Only
value of 2500 g to distinguish “normal” from “low” birth four of our infants with “normal” weight at birth could
weights since the gestational age of the infants ranged be considered to have intrauterine growth retardation
from 36 to 41 weeks. A weight of 2500 g is in approxi- (IUGR), as defined in the tables presently used in our
mately the 25th percentile at 36 weeks but well below country [3]. The issue of the relationship between IUGR
the 3rd percentile at 41 weeks. This is important because and nephron number and size is important and not di-
other studies indicate that intrauterine growth retarda- rectly addressed in our paper. However, our results indi-
tion (IUGR), not low birth weight per se, is associated cate a significant correlation between birth weight and
with oligonephronia in humans [2] (abstract; Leroy et the number of nephrons, as shown by others, and a sig-
al, Ped Nephrol 6:C21, 1992) as well as in rats [3]. It nificant inverse correlation between the number and the
would be interesting to know if the difference in nephron size of glomeruli, a novel finding, as correctly noted by
numbers remained the same if the infants were divided Dr. Haycock.
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